1Mossner R,Henneberg A,Schmitt A,et al.Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease[J].Mol Psychiatry,2001,6:350-352.
2Barrero FJ,Ampuero I,Morales B,et al.Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene(CNR1)[J].Pharmacogenomics Journal,2005,5(2):135-141.
3Burn DJ,Tiangyou W,Allcock LM.,et al.Allelie variation of a functional polymorphism in the serotonin transportergene and depression in Parkinson's disease[J].Parkinsonism and Related Disorders,2006,12(3):139-141.
4Austin MP,Mitchell P,HadziPavlovic D.et al.Effect of apomorphine on motor and cognitive function in melancholic patients:apreliminary report[J].Psychiatry Res,2000,97:207-215.
5Slaughter JR.Slaughter KA,Prevalence,clinical manifestations.etiology.and treatment of depression in Parkinson's disease[J].Neuropsychiaty clin Neurosci,2001,13(2):187.
6Mayberg HS,Starkstein SE,Sadzot B,et al.Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease[J].Ann Neurol,1990,28(1):57.
7Cote L Depression:impact and management by the patient and family[J].Neurology,1999,52(7):7.
8Sehanrnlan AG.van den Akker M,Ensinek KTJL,et al.Increased risk of Parkinson's disease after depression:A retrospective cohort study[J].Neurology,2002,58:1501.
9Philippe R,Miroslava D,Andrew L,et al.Depression in Parkinson's disease:loss of dopamine and noradrenaline inne rvation in the limbic system[J].Brain,2005,128:1314-1322.
10Giladi N,Trevea T.A,Paleacu D,et al.Risk factors for dementia,depression and psychosis in long-standing Parkinson's disease[J].Journal of Neural Transm,2000,107:59-71.
同被引文献7
1Schrag A. Psychiatric aspects of Parkinson's disease, an update [J]. J Neurol, 2004,251(7):795-804.
2Scholtissen B, Verhey F R, Steinbusch H W, et al. Serotonergic mechanisms in Parkinson's disease: opposing results from preelinical and clinical data [J]. J Neural Transm, 2006,113 (1) : 59-73.
3Hesse S, Barthel H, Schwarz J, et al. Advances in in vivo imaging of serotonergic neurons in neuropsychiatrie disorders [J]. Neurosci Biobehav Rev, 2004,28(6) :547 -563.
4Maeda T, Nagata K, Yoshida Y, et al. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered L-dopa [J]. Brain Res, 2005,1046(1-2) : 230-233.
5Carlsson T, Carta M, Mufioz A, et al. Impact of grafted serotonin and dopamine neurons on development of L-dopa-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration [J]. Brain, 2009,132(2) : 319 335.
6Carta M, Carlsson T, Kirik D, et al. Dopamine released from 5- HT terminals is the cause of L-dopa-induced dyskinesia in parkinsonian rats [J]. Brain, 2007,130(7) : 1819-1833.
7Pardo B, Mena M A, Casarejos M J, et al. Toxic effects of L-dopa on mesencephalic cell cultures: protection with antioxidants [J]. Brain Res, 1995,682 (1 2) : 133-143.
